Replimune RP1 melanoma BLA wins favorable 10-3 FDA advisory panel vote on IGNYTE efficacy data

• Replimune’s RP1 melanoma filing cleared a key FDA advisory committee hurdle, with a 10-3 vote backing the IGNYTE efficacy package as evaluable.
• Results were already reviewed at the meeting, supporting RP1 with nivolumab for patients whose disease progressed on prior anti-PD-1 therapy.
• Panel discussion focused on whether the single-arm study supports a reliable, clinically meaningful benefit with signs of systemic anti-tumor activity.
• FDA target action date for the Class 1 resubmission is Aug. 2, 2026, setting a near-term catalyst for the stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607301815PRIMZONEFULLFEED9801385) on July 30, 2026, and is solely responsible for the information contained therein.